JPMorgan Chase & Co. Reiterates "Underweight" Rating for Replimune Group (NASDAQ:REPL)

Key Points

• JPMorgan Chase & Co. has reiterated its "underweight" rating for Replimune Group, amid a mixed outlook from other analysts.
• Replimune Group's recent financial performance shows a loss of $0.95 earnings per share, missing the analyst consensus estimate of ($0.83).
• The average target price for Replimune Group's stock is currently at $6.50, with most analysts rating the stock as a Hold.

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "underweight" rating reissued by investment analysts at JPMorgan Chase & Co. in a research report issued on Friday,Benzinga reports.

Several other analysts have also recently weighed in on the company. Cantor Fitzgerald raised Replimune Group from a "neutral" rating to an "overweight" rating in a report on Wednesday, July 30th. Leerink Partners reissued a "market perform" rating and set a $3.00 price objective (down from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. HC Wainwright reissued a "neutral" rating on shares of Replimune Group in a report on Monday, September 8th. Piper Sandler cut Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a report on Tuesday, July 22nd. Finally, BMO Capital Markets lowered Replimune Group from an "outperform" rating to an "underperform" rating and decreased their target price for the stock from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $6.50.

Replimune Group Stock Performance

Replimune Group stock opened at $3.46 on Friday. The stock has a market capitalization of $270.07 million, a price-to-earnings ratio of -1.07 and a beta of 0.51. Replimune Group has a 12-month low of $2.68 and a 12-month high of $17.00. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The stock has a 50-day simple moving average of $6.29 and a 200 day simple moving average of $8.27.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). On average, research analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at approximately $721,556.16. The trade was a 6.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after purchasing an additional 1,879 shares during the period. Deutsche Bank AG grew its position in shares of Replimune Group by 0.4% in the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock valued at $5,496,000 after purchasing an additional 2,140 shares during the period. Arizona State Retirement System grew its position in shares of Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock valued at $151,000 after purchasing an additional 2,545 shares during the period. MetLife Investment Management LLC grew its position in shares of Replimune Group by 7.8% in the 1st quarter. MetLife Investment Management LLC now owns 40,598 shares of the company's stock valued at $396,000 after purchasing an additional 2,939 shares during the period. Finally, Corebridge Financial Inc. grew its position in shares of Replimune Group by 11.0% in the 1st quarter. Corebridge Financial Inc. now owns 33,584 shares of the company's stock valued at $327,000 after purchasing an additional 3,317 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.